Even though larger cohorts of patients with “control diseases” are required to validate statistically this difference for each inflammatory syndrome, these data strongly suggest that inflammasome activation in response to PKC inhibitors is not due to underlying inflammation but is specific to FMF patients. This evidence concerns the gene PRRT2 and familial Mediterranean fever.